GAMMA Investing LLC Grows Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

GAMMA Investing LLC grew its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 20,224.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 126,012 shares of the specialty pharmaceutical company's stock after purchasing an additional 125,392 shares during the period. GAMMA Investing LLC owned about 0.21% of Jazz Pharmaceuticals worth $15,644,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Focus Partners Wealth purchased a new stake in Jazz Pharmaceuticals in the fourth quarter worth $551,000. Moloney Securities Asset Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $464,000. Summit Trail Advisors LLC bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $539,000. Atria Investments Inc raised its holdings in shares of Jazz Pharmaceuticals by 19.5% in the fourth quarter. Atria Investments Inc now owns 2,732 shares of the specialty pharmaceutical company's stock valued at $336,000 after acquiring an additional 445 shares in the last quarter. Finally, Harvey Capital Management Inc. bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $3,134,000. Hedge funds and other institutional investors own 89.14% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on JAZZ shares. Truist Financial lifted their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Barclays restated an "overweight" rating and issued a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. JPMorgan Chase & Co. lifted their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Piper Sandler restated an "overweight" rating and issued a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Finally, Robert W. Baird decreased their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $184.00.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $123.75, for a total transaction of $185,625.00. Following the sale, the chief executive officer now owns 440,307 shares in the company, valued at approximately $54,487,991.25. The trade was a 0.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Seamus Mulligan bought 100,000 shares of the company's stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the transaction, the director now owns 100,000 shares of the company's stock, valued at $9,826,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 6,543 shares of company stock worth $845,628. Insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $111.13 on Friday. Jazz Pharmaceuticals plc has a one year low of $95.49 and a one year high of $148.06. The company has a market capitalization of $6.85 billion, a PE ratio of 15.65, a P/E/G ratio of 1.04 and a beta of 0.33. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company has a 50-day simple moving average of $108.09 and a two-hundred day simple moving average of $121.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The business had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. During the same quarter in the previous year, the firm posted $2.68 EPS. Jazz Pharmaceuticals's revenue was down .5% on a year-over-year basis. Research analysts expect that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.